Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 29.

Journal Article

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Doepfner, M., Breuer, D., Ose, C. and Fischer, R. (2011). Modified-release methylphenidate in routine treatment. Effectiveness and tolerability in a study in children and adolescents with ADHD (attention deficit hyperactivity syndrome). Mon.schr. Kinderheilkd., 159 (11). S. 1119 - 1125. NEW YORK: SPRINGER. ISSN 1433-0474

Eisert, A., Scheffier, M., Gogl, L., Frank, R., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buettner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Oncol. Res. Treat., 38. S. 16 - 17. BASEL: KARGER. ISSN 2296-5262

Eisert, A., Scheffler, M., Frank, R., Gogl, L., Scheel, A., Merkelbach-Bruse, S., Michels, S., Fischer, R., Buttner, R. and Wolf, J. (2015). Clinical and genetic presentation of high-level cMET-amplified Non-small cell lung cancer (NSCLC) with adenocarcinoma histology. Eur. J. Cancer, 51. S. S646 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Frank, R., Scheffler, M., Michels, S., Eisert, A., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. D., Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 51. S. S645 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Frank, R., Scheffler, M., Michels, S., Eisert, A., Gogl, L., Fischer, R., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Geist, T., Heukamp, L., Buettner, R. and Wolf, J. (2015). KEAP1-mutations and NFE2L2-mutations in patients with non-small cell lung cancer (NSCLC). Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics. Ann. Oncol., 33. S. S56 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Gogl, L., Scheffier, M., Ihle, M., Michels, S., Fischer, R., Serke, M., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Oncol. Res. Treat., 38. S. 269 - 270. BASEL: KARGER. ISSN 2296-5262

Gogl, L., Scheffler, M., Ihle, M., Michels, S. Y. F., Fischer, R., Serke, M. H., Gerigk, U., Woempner, C., Krueger, S., Kaminsky, B., Schulte, W., Hoeffken, G., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2015). Clinical and molecular characteristics of non-small cell lung cancer in patients harboring CTNNB1 mutations. Eur. J. Cancer, 51. S. S647 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Michels, S., Fassunke, J., Scheffler, M., Sueptitz, J., Fischer, R., DeMary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2016). The Network Genomic Medicine first joint cost-effectiveness and outcome evaluation based on multiplex lung cancer genotyping. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. -P, Buettner, R. and Wolf, J. (2015). Comprehensive multiplex genotyping in lung cancer: challenges and opportunities of interdisciplinary networking using the example of the Network Genomic Medicine. Oncol. Res. Treat., 38. S. 268 - 269. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Kron, F., Scheffler, M., Michels, S., Sueptitz, J., Fischer, R., Merkelbach-Bruse, S., Scheel, A., De-Mary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2015). Broad implementation of next generation sequencing based lung cancer genotyping in clinical routine within a nationwide health care provider network in Germany. Eur. J. Cancer, 51. S. S597 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Scheffler, M., Glossmann, J., Fischer, R., Michels, S., Nagoya, L., Hallek, M., Zander, T. and Wolf, J. (2016). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Scheffler, M., Mueller, D., Glossmann, J. -P., Fischer, R., Michels, S., Nogova, L., Hallek, M., Zander, T. and Wolf, J. (2017). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer, 108. S. 134 - 140. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Michels, S., Brandes, V, Thurat, M., Nogova, L., Scheffler, M., Fischer, R., Merkelbach-Bruse, S., Hellmich, M., Buettner, R. and Wolf, J. (2016). EATON: An open-label, multicenter, phase I dose-escalation trial of EGF816 and trametinib in patients with non-small cell lung cancer and acquired EGFR p.T790M positive resistance to 1st or 2nd generation EGFR TKI therapy - a trial in preparation. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Michels, S., Fischer, R., Heydt, C., Ihle, M., Scheffler, M., Scheel, A., Ortiz-Cuaran, S., Nogova, L., Brandes, V, Sos, M., Buettner, R., Merkelbach-Bruse, S. and Wolf, J. (2016). Mechanisms of primary and acquired resistance to 3rd generation EGFR TKI treatment in EGFR mutated lung adenocarcinoma. Oncol. Res. Treat., 39. S. 252 - 254. BASEL: KARGER. ISSN 2296-5262

Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262

Michels, S., Thurat, M., Schmalz, P., Pereira, E., Scheffler, M., Fischer, R., Sebastian, M., Abreu, D. R., Carcereny, E., Corral, J. J., Felip, E., Grohe, C., Insa, A., Thomas, M., Reck, M., Rothschild, S., Brandes, V, Nogova, L., Merkelbach-Bruse, S., Massuti, B., Buettner, R., Rosell, R. and Wolf, J. (2016). EUCROSS: A European phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations - Preliminary results. Oncol. Res. Treat., 39. S. 209 - 211. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Bitter, E., Michels, S., Fischer, R., Scheffler, M., Gardizi, M., Brandes, V., Scheel, A. H., Kambartel, K., Krueger, S. ORCID: 0000-0002-1658-5993, Serke, M., Isaacs, R., Porter, D., Buettner, R., Thomas, R. K. and Wolf, J. (2017). Fibroblast kinase 1-3 inhibitor BGJ398 in patients with FGFR1 amplified squamous non-small cell lung cancer treated in a phase I study: evaluation of tumor tissue and response at a single center. Oncol. Res. Treat., 40. S. 137 - 139. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Ihle, M. A., Merkelbach-Bruse, S., Michels, S., Nogova, L., Kron, A., Fischer, R., Serke, M., Ko, Y. -D., Gerigk, U., Schulte, W., Sebastian, M., Riedel, R., Holzem, A., Kambartel, K. -O., Buettner, R. and Wolf, J. (2017). Genetic heterogeneity of KRAS-mutated NSCLC leads to different responses to first-line platinum-based chemotherapy. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele-Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., Fischer, R., Grosse-Onnebrink, J., Hammermann, J., Hebestreit, H., Hogardt, M., Huegel, C., Hug, M., Illing, S., Jung, A., Kahl, B., Koitschev, A., Mahlberg, R., Mainz, J. G., Mattner, F., Mehl, A., Moeller, A., Muche-Borowski, C., Nuesslein, T., Puderbach, M., Renner, S., Rietschel, E., Ringshausen, F. C., Schmidt, S., Sedlacek, L., Sitter, H., Smaczny, C., Tuemmler, B., Vonberg, R., Wielpuetz, M. O., Wilkens, H., Wollschlaeger, B., Zerlik, J., Dueesberg, U. and van Koningsbruggen-Rietschel, S. (2018). CF Lung Disease - a German S3 Guideline: Module 2: Diagnostics and Treatment in Chronic Infection with Pseudomonas aeruginosa. Pneumologie, 72 (5). S. 347 - 393. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

This list was generated on Fri Apr 19 14:33:07 2024 CEST.